David is a passionate, mission-driven finance leader. He has a successful track record assisting CEOs, and their teams, in delivering promised clinical and financial results to all stakeholders.
Most recently as the CFO of Atorvia Health technologies, a pharmaceutical development company, David established partnerships with leading universities, executed licensing agreements for their novel preclinical assets, and built the related business plans, financial models, and budgets. David has assisted in securing nondilutive grants and completed the Massachusetts Biotechnology Council’s accelerator program at MIT. The program positioned Atorvia for a Series A round to fund preclinical studies supporting a phase 1 application with the FDA.
Prior to Atorvia, David served in CFO roles for early-stage private and public digital health companies with SaaS-based solutions ranging from population health to clinician workflow management. For example, as the CFO of Augmedix (NASDAQ: AUGX), Google’s “Smart Glass” partner, he assisted in raising a Series B round, including a venture debt line. The Series B and debt line totaled $72M.
During his CFO career, David assisted two founding CEOs in obtaining private capital, executing strategies, and completing IPOs on NASDAQ. Meris, a clinical reference lab, was one of the top-performing US IPOs and was eventually acquired by Quest Diagnostics, and MECON, a healthcare data provider, was acquired by GE six years after the IPO. Upon the GE acquisition, David assumed the CEO role for the division reporting to Jeff Immelt.
David began his career as an auditor with Price Waterhouse in their Silicon Valley Office, where he obtained his CPA license.